CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/conference?src=hash" target="_blank"gt;#conferencelt;/agt;–Goldfinch Bio, Inc., a biotechnology company focused on developing
precision therapies for patients with kidney diseases, today announced
that Anthony Johnson, M.D., President and Chief Executive Officer of
Goldfinch Bio, will present at the following investor conferences in
June:
-
The Jefferies 2019 Global Healthcare Conference on Friday, June 7,
2019, at 8:00 a.m. ET in New York, NY. -
The Raymond James Life Sciences & MedTech Conference on Wednesday,
June 19, 2019, at 11:30 a.m. ET in New York, NY.
About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on
discovering and developing precision therapies for patients with kidney
diseases. Just as the goldfinch has long been a symbol of healing and
renewal and was a prominent figure of the Renaissance, Goldfinch Bio is
leading a new age of therapeutic discovery to transform the treatment
paradigm for patients with kidney diseases. Goldfinch was launched in
2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass.
For more information, please visit www.goldfinchbio.com.
Contacts
The Yates Network
Gina Nugent
617-460-3579
gina@theyatesnetwork.com